Click here for slides on this topic


Interleukin-6 (IL-6)

An inflammatory lymphokine produced by T cells, fibroblasts and activated macrophages.
The following content matched the glossary term: Interleukin-6 (IL-6)

The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers

Top

Samaropoulos XF, Light L, Ambrosius WT, Marcovina SM, Probstfield J, Jr DC. The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers. Diabetes Res Clin Pract. 2011 Oct 21. [Epub ahead of print]. To determine whether intensive risk factor management reduced markers of inflammation in middle-aged and older people with type 2 diabetes who either had, or were at risk for cardiovascular disease (CVD), and whether these effects were mediated by adiposity.

Thiazolidinedione (Pioglitazone) blocks P. gingivalis- and F. nucleatum but not E. coli lipopolysaccharide (LPS)-induced interleukin-6 (IL-6) production

Top

Yamaguchi M, Nishimura F, Naruishi H, Soga Y, Kokeguchi S, Takashiba S. Thiazolidinedione (Pioglitazone) blocks P. gingivalis- and F. nucleatum, but not E. coli, lipopolysaccharide (LPS)-induced interleukin-6 (IL-6) production in adipocytes. J Dent Res. 2005;84:240-244. An elevated level of C-reactive protein (CRP) predicts the future development of coronary heart disease. Periodontitis appears to up-regulate CRP. CRP is produced by hepatocytes in response to interleukin-6 (IL-6). A major source of IL-6 in obese subjects is adipocytes.

Inflammatory Markers and Risk of Developing Type 2 Diabetes in Women

Top

Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Inflammatory Markers and Risk of Developing Type 2 Diabetes in Women. Diabetes. 2004;53:693-700. We conducted a prospective, nested, case-control study of inflammatory markers as predictors of type 2 diabetes among 32,826 women who provided blood samples in 1989 through 1990 in the Nurses' Health Study. Among women free of diabetes, cardiovascular disease, or cancer at baseline, 737 had developed diabetes by 2000.

Insulin Resistance, Inflammation, and Serum Fatty Acid Composition

Top

Fernández-Real J-M, Broch M, Vendrell J, Ricart W. Insulin Resistance, Inflammation, and Serum Fatty Acid Composition. Diabetes Care. 2003;26:1362-1368. Fatty acids (FAs) have been involved in the development of chronic inflammatory conditions such as insulin resistance and obesity. However, the relation among insulin resistance, obesity, inflammatory activity (circulating interleukin [IL]-6) and dietary FAs has been scarcely studied in otherwise healthy subjects.

Interleukin-6 Induces Cellular Insulin Resistance in Hepatocytes

Top

Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6 Induces Cellular Insulin Resistance in Hepatocytes. Diabetes. 2002;51:3391-3399. Interleukin (IL)-6 is one of several proinflammatory cytokines that have been associated with insulin resistance and type 2 diabetes. A two- to threefold elevation of circulating IL-6 has been observed in these conditions. Nonetheless, little evidence supports a direct role for IL-6 in mediating insulin resistance.

Suppression of Nuclear Factor-kappaB and Stimulation of Inhibitor kappaB by Troglitazone

Top

Ghanim H, Garg R, Aljada A, et al. Suppression of Nuclear Factor-B and Stimulation of Inhibitor B by Troglitazone: Evidence for an Anti-inflammatory Effect and a Potential Antiatherosclerotic Effect in the Obese. Endocrinology. 2001;86:1306-1312. To elucidate whether troglitazone exerts an antiinflammatory effect in humans, in vivo, we investigated the suppression of nuclear factor kappaB (NFkappaB) in mononuclear cells (MNC) by this drug.



Slide Library Results

Search Results for: Interleukin-6 (IL-6) Slides Found: 1
Effect of Diet and Exercise on Adipokines